When was Geneoscopy founded?

Geneoscopy was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Geneoscopy located?

Geneoscopy is headquartered in St. Louis, United States.

How many employees does Geneoscopy have?

As of May 31, 2026, the latest employee count at Geneoscopy is 71.

Is Geneoscopy a funded company?

Geneoscopy is a funded company, having raised a total of $219M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 22, 2016.

When was the latest funding round of Geneoscopy?

Geneoscopy's latest funding was a $***** Series C round on Jan 08, 2025, with participation from 9 investors.

Where does Geneoscopy rank among its competitors?

Geneoscopy ranks 4th amongst 398 active competitors, of which 130 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Geneoscopy?

Geneoscopy's top competitors include Denali Therapeutics, Caris Life Sciences and Personalis. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Geneoscopy - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of non-invasive biomarker tests for colorectal cancer. The flagship assay analyzes stool samples for a panel of disease-associated mRNA biomarkers using a proprietary diagnostic algorithm to detect colorectal cancer. The company plans that its assay will be used to screen patients in need of a more invasive colonoscopy.

Website: geneoscopy.com
Social
Email ID: *****@gmail.com

Key Metrics

Founded Year

2015

Location

St. Louis, United States

Stage

Series C

Total Funding

$219M in 6 rounds

Latest Funding Round

Series C, Jan 08, 2025, $*****

Investors

Cultivation Capital & 19 more

Ranked

4^th among 398 active competitors

Employee Count

71 as on May 31, 2026

Similar Companies

Denali Therapeutics & 548 more

View Geneoscopy's full profile

Geneoscopy has raised a total funding of $219M over 6 rounds. Its first funding round was on Jun 22, 2016. Its latest funding round was a Series C round on Jan 08, 2025 for $*****. 9 investors participated in its latest round. Geneoscopy has 20 institutional investors.

Here is the list of recent funding rounds of Geneoscopy:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2025	6901630	Series C	8375446	8545780	2248718	1707977
Nov 16, 2021	5801182	Series B	9805419	6432456	2081758	LabCorp & 4 more
Nov 16, 2021	2550853	Conventional Debt	4050659	5612859	9382785	LightChain Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Geneoscopy's funding rounds and investors

The founders of Geneoscopy is Erica Barnell.

Here are the details of Geneoscopy's key team members:

Erica Barnell: Founder & CEO of Geneoscopy.
Contact Info: 1 email address

View details of Geneoscopy's Founder profiles and Board Members

Geneoscopy's employee count trend

Geneoscopy has 71 employees as of May 26. Here is Geneoscopy's employee count trend over the years:

Uncover Geneoscopy's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Geneoscopy include Denali Therapeutics, Caris Life Sciences and Personalis. Here is the list of Top 10 competitors of Geneoscopy, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
3rd	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	70/100
4th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	Innovatus Capital Partners, Morningside & 18 others	67/100
5th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Orbimed, Novartis & 10 others	66/100
6th	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	RA Capital Management, Perceptive Advisors ... & 65 others	66/100
7th	Unilabs 2000, Geneva (Switzerland), Acquired	Provider of diagnostics services company	-	Digital Pharma Lab, Nordic Capital & 1 others	65/100
8th	ACT Genomics 2014, Taipei (Taiwan), Acquired	Clinical and research services in genomics for cancer	$20.5M	Hotung Investment Holdings, CLSA Capital Partners ... & 9 others	64/100
9th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, Khosla Ventures & 16 others	63/100
10th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Ironwood Capital, Enhanced Capital & 3 others	63/100